Evidence map›Paper›PMID 25165106›Full record

ArticleJournal of virology2014

Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope.

Chitra Upadhyay, Luzia M Mayr, Jing Zhang, Rajnish Kumar, Miroslaw K Gorny, Arthur Nádas, Susan Zolla-Pazner, Catarina E Hioe

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 50 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Computational-guided determination of the functional role of 447-52D long CDRH3.Protein engineering, design & selection : PEDS · 2018
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Chitra UpadhyayVeterans Affairs New York Harbor Healthcare System, New York, New York, USA Department of Pathology, New York University School of Medicine, New York, New York, USA.
Luzia M MayrVeterans Affairs New York Harbor Healthcare System, New York, New York, USA Department of Pathology, New York University School of Medicine, New York, New York, USA.
Jing ZhangDepartment of Microbiology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, Sichuan, People's Republic of China.
Rajnish KumarVeterans Affairs New York Harbor Healthcare System, New York, New York, USA Department of Pathology, New York University School of Medicine, New York, New York, USA.
Miroslaw K GornyVeterans Affairs New York Harbor Healthcare System, New York, New York, USA Department of Pathology, New York University School of Medicine, New York, New York, USA.
Arthur NádasInstitute of Environmental Medicine, New York University School of Medicine, New York, New York, USA.
Susan Zolla-PaznerVeterans Affairs New York Harbor Healthcare System, New York, New York, USA Department of Pathology, New York University School of Medicine, New York, New York, USA.
Catarina E HioeVeterans Affairs New York Harbor Healthcare System, New York, New York, USA Department of Pathology, New York University School of Medicine, New York, New York, USA catarina.hioe@nyumc.org.
VA NY Harbor Healthcare System · USNew York University · USSichuan University · CN

Funding

Vaccines to Induce Functional Antibodies Targeting the V2 Loop P01AI100151 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WANG, SHIXIA · 2012 to 2017
$15.4M
Contributions of anti-V2 antibodies in protection against HIVR01AI102740 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HIOE, CATARINA E · 2012 to 2016
$2.5M
NIAID NIH HHS HIVRAD P01 AI100151NIAID NIH HHS P01 AI100151NIAID NIH HHS R01 AI102740
6 · The paper itself

Abstract

unlabelledBroadly neutralizing antibodies targeting the HIV-1 envelope (Env) are key components for protection against HIV-1. However, many cross-reactive epitopes are often occluded. This study investigates the mechanisms contributing to the masking of V2i (variable loop V2 integrin) epitopes compared to the accessibility of V3 epitopes. V2i are conformation-dependent epitopes encompassing the integrin α4β7-binding motif on the V1V2 loop of HIV-1 Env gp120. The V2i monoclonal antibodies (MAbs) display extensive cross-reactivity with gp120 monomers from many subtypes but neutralize only few viruses, indicating V2i's cryptic nature. First, we asked whether CD4-induced Env conformational changes affect V2i epitopes similarly to V3. CD4 treatment of BaL and JRFL pseudoviruses increased their neutralization sensitivity to V3 MAbs but not to the V2i MAbs. Second, the contribution of N-glycans in masking V2i versus V3 epitopes was evaluated by testing the neutralization of pseudoviruses produced in the presence of a glycosidase inhibitor, kifunensine. Viruses grown in kifunensine were more sensitive to neutralization by V3 but not V2i MAbs. Finally, we evaluated the time-dependent dynamics of the V2i and V3 epitopes. Extending the time of virus-MAb interaction to 18 h before adding target cells increased virus neutralization by some V2i MAbs and all V3 MAbs tested. Consistent with this, V2i MAb binding to Env on the surface of transfected cells also increased in a time-dependent manner. Hence, V2i and V3 epitopes are highly dynamic, but distinct factors modulate the antibody accessibility of these epitopes. The study reveals the importance of the structural dynamics of V2i and V3 epitopes in determining HIV-1 neutralization by antibodies targeting these sites. IMPORTANCE: Conserved neutralizing epitopes are present in the V1V2 and V3 regions of HIV-1 Env, but these epitopes are often occluded from Abs. This study reveals that distinct mechanisms contribute to the masking of V3 epitopes and V2i epitopes in the V1V2 domain. Importantly, V3 MAbs and some V2i MAbs display greater neutralization against relatively resistant HIV-1 isolates when the MAbs interact with the virus for a prolonged period of time. Given their highly immunogenic nature, V3 and V2i epitopes are valuable targets that would augment the efficacy of HIV vaccines.

Indexed as

Antibodies, MonoclonalAntibodies, NeutralizingCell LineEpitopesHIV-1HIV AntibodiesHIV Envelope Protein gp120HumansNeutralization TestsProtein BindingAntibodies, MonoclonalAntibodies, NeutralizingEpitopesHIV AntibodiesHIV Envelope Protein gp120

Identifiers

PMID25165106
PMCPMC4248937
OpenAlexW1999554971

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.